The Experts below are selected from a list of 279 Experts worldwide ranked by ideXlab platform
Martin Miner - One of the best experts on this subject based on the ideXlab platform.
-
Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
Postgraduate medicine, 2013Co-Authors: Gary Blick, Rajib K. Bhattacharya, Mohit Khera, Harvey Kushner, Martin MinerAbstract:AbstractBackground: Although hypogonadism is common in men with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), Testosterone levels after Testosterone replacement therapy (TRT) in this population have not been reported. Methods: The Testim Registry in the United States (TRiUS) was the first prospective, observational registry of men with hypogonadism who were prescribed TRT. The TRiUS cohorts with (n = 82) and without (n = 767) HTV/AIDS were followed during 12 months of treatment with Testim® (1% Testosterone gel; Auxilium Pharmaceuticals, Inc.). Total Testosterone (TT) and free Testosterone levels, symptoms of depression, sexual function, body composition profiles, and prostate-specific antigen levels were evaluated. Results: The HIV/AIDS and non-HIV/AIDS cohorts differed at baseline in age (48.3 vs 52.5 years), TT level (13.0 vs 9.6 nmol/L), duration of hypogonadism (27.1 vs 14.6 months), prior TRT (36.6% vs 22.6%), body mass index (26.5 vs 32.0 kg/m2), and antidepressant (...
-
12-month observation of Testosterone replacement effectiveness in a general population of men.
Postgraduate medicine, 2013Co-Authors: Martin Miner, Rajib K. Bhattacharya, Gary Blick, Harvey Kushner, Mohit KheraAbstract:AbstractBackground: Testosterone decline becomes more prevalent as men age and symptomatic Testosterone deficiency is associated with potentially serious comorbidities. Despite limitations, registries can provide an opportunity to accumulate data regarding disease management in a typical patient population, including diagnosis, treatment, and outcomes. Materials and Methods: The Testim Registry in the United States (TRiUS) was a prospective, 12-month, observational cohort registry of men prescribed Testim® (1% Testosterone gel; Auxilium Pharmaceuticals, Inc.) for the first time; patients previously on other forms of Testosterone replacement therapy (TRT) were eligible to participate in the study as well. The registry recorded total Testosterone (TT) and free Testosterone (FT) levels, prostate-specific antigen (PSA), sexual function, mood/depression, and cardiometabolic and anthropometric criteria before and after TRT. Changes over time were analyzed by analysis of variance, and linear regression and Pears...
-
changes in prostate specific antigen in hypogonadal men after 12 months of Testosterone replacement therapy support for the prostate saturation theory
The Journal of Urology, 2011Co-Authors: Mohit Khera, Rajib K. Bhattacharya, Gary Blick, Harvey Kushner, Dat Nguyen, Martin MinerAbstract:Purpose: We measured prostate specific antigen after 12 months of Testosterone replacement therapy in hypogonadal men.Materials and Methods: Data were collected from the TRiUS (Testim® Registry in the United States), an observational registry of hypogonadal men on Testosterone replacement therapy (849). Participants were Testim naive, had no prostate cancer and received 5 to 10 gm Testim 1% (Testosterone gel) daily.Results: A total of 451 patients with prostate specific antigen and total Testosterone values were divided into group A (197 with total Testosterone less than 250 ng/dl) and group B (254 with total Testosterone 250 ng/dl or greater). The groups differed significantly in free Testosterone and sex hormone-binding globulin, but not in age or prostate specific antigen. In group A but not group B prostate specific antigen correlated significantly with total Testosterone (r = 0.20, p = 0.005), free Testosterone (r = 0.22, p = 0.03) and sex hormone-binding globulin (r = 0.59, p = 0.002) at baseline. A...
-
Baseline data from the TRiUS registry: symptoms and comorbidities of Testosterone deficiency.
Postgraduate medicine, 2011Co-Authors: Martin Miner, Mohit Khera, Rajib K. Bhattacharya, Gary Blick, Harvey KushnerAbstract:AbstractBackground: Testosterone deficiency (TD) is prevalent among men seeking medical attention and may be associated with other comorbidities. Objective: The Testim® Registry in the United States (TRiUS), a large, multicenter, prospective, 12-month observational cohort registry, was established to quantify symptoms and comorbidities of hypogonadal men in real-world clinical settings and to evaluate the effect of Testosterone replacement therapy (TRT). Methods: Eligible TRiUS participants were hypogonadal men prescribed Testim® (1% Testosterone gel) for the first time. Evaluated baseline parameters included: total Testosterone (TT), free Testosterone (FT), sex hormone-binding globulin (SHBG), prostate-specific antigen (PSA), anthropometrics (height, weight, waist, hip, and body mass index [BMI]), lipids, blood glucose, sexual dysfunction, mood/depression, and cardiovascular and metabolic risk factors. Parameters were correlated to TT and age using bivariate correlation and to the combination of TT and a...
Mohit Khera - One of the best experts on this subject based on the ideXlab platform.
-
Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
Postgraduate medicine, 2013Co-Authors: Gary Blick, Rajib K. Bhattacharya, Mohit Khera, Harvey Kushner, Martin MinerAbstract:AbstractBackground: Although hypogonadism is common in men with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), Testosterone levels after Testosterone replacement therapy (TRT) in this population have not been reported. Methods: The Testim Registry in the United States (TRiUS) was the first prospective, observational registry of men with hypogonadism who were prescribed TRT. The TRiUS cohorts with (n = 82) and without (n = 767) HTV/AIDS were followed during 12 months of treatment with Testim® (1% Testosterone gel; Auxilium Pharmaceuticals, Inc.). Total Testosterone (TT) and free Testosterone levels, symptoms of depression, sexual function, body composition profiles, and prostate-specific antigen levels were evaluated. Results: The HIV/AIDS and non-HIV/AIDS cohorts differed at baseline in age (48.3 vs 52.5 years), TT level (13.0 vs 9.6 nmol/L), duration of hypogonadism (27.1 vs 14.6 months), prior TRT (36.6% vs 22.6%), body mass index (26.5 vs 32.0 kg/m2), and antidepressant (...
-
12-month observation of Testosterone replacement effectiveness in a general population of men.
Postgraduate medicine, 2013Co-Authors: Martin Miner, Rajib K. Bhattacharya, Gary Blick, Harvey Kushner, Mohit KheraAbstract:AbstractBackground: Testosterone decline becomes more prevalent as men age and symptomatic Testosterone deficiency is associated with potentially serious comorbidities. Despite limitations, registries can provide an opportunity to accumulate data regarding disease management in a typical patient population, including diagnosis, treatment, and outcomes. Materials and Methods: The Testim Registry in the United States (TRiUS) was a prospective, 12-month, observational cohort registry of men prescribed Testim® (1% Testosterone gel; Auxilium Pharmaceuticals, Inc.) for the first time; patients previously on other forms of Testosterone replacement therapy (TRT) were eligible to participate in the study as well. The registry recorded total Testosterone (TT) and free Testosterone (FT) levels, prostate-specific antigen (PSA), sexual function, mood/depression, and cardiometabolic and anthropometric criteria before and after TRT. Changes over time were analyzed by analysis of variance, and linear regression and Pears...
-
changes in prostate specific antigen in hypogonadal men after 12 months of Testosterone replacement therapy support for the prostate saturation theory
The Journal of Urology, 2011Co-Authors: Mohit Khera, Rajib K. Bhattacharya, Gary Blick, Harvey Kushner, Dat Nguyen, Martin MinerAbstract:Purpose: We measured prostate specific antigen after 12 months of Testosterone replacement therapy in hypogonadal men.Materials and Methods: Data were collected from the TRiUS (Testim® Registry in the United States), an observational registry of hypogonadal men on Testosterone replacement therapy (849). Participants were Testim naive, had no prostate cancer and received 5 to 10 gm Testim 1% (Testosterone gel) daily.Results: A total of 451 patients with prostate specific antigen and total Testosterone values were divided into group A (197 with total Testosterone less than 250 ng/dl) and group B (254 with total Testosterone 250 ng/dl or greater). The groups differed significantly in free Testosterone and sex hormone-binding globulin, but not in age or prostate specific antigen. In group A but not group B prostate specific antigen correlated significantly with total Testosterone (r = 0.20, p = 0.005), free Testosterone (r = 0.22, p = 0.03) and sex hormone-binding globulin (r = 0.59, p = 0.002) at baseline. A...
-
Baseline data from the TRiUS registry: symptoms and comorbidities of Testosterone deficiency.
Postgraduate medicine, 2011Co-Authors: Martin Miner, Mohit Khera, Rajib K. Bhattacharya, Gary Blick, Harvey KushnerAbstract:AbstractBackground: Testosterone deficiency (TD) is prevalent among men seeking medical attention and may be associated with other comorbidities. Objective: The Testim® Registry in the United States (TRiUS), a large, multicenter, prospective, 12-month observational cohort registry, was established to quantify symptoms and comorbidities of hypogonadal men in real-world clinical settings and to evaluate the effect of Testosterone replacement therapy (TRT). Methods: Eligible TRiUS participants were hypogonadal men prescribed Testim® (1% Testosterone gel) for the first time. Evaluated baseline parameters included: total Testosterone (TT), free Testosterone (FT), sex hormone-binding globulin (SHBG), prostate-specific antigen (PSA), anthropometrics (height, weight, waist, hip, and body mass index [BMI]), lipids, blood glucose, sexual dysfunction, mood/depression, and cardiovascular and metabolic risk factors. Parameters were correlated to TT and age using bivariate correlation and to the combination of TT and a...
Gary Blick - One of the best experts on this subject based on the ideXlab platform.
-
Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
Postgraduate medicine, 2013Co-Authors: Gary Blick, Rajib K. Bhattacharya, Mohit Khera, Harvey Kushner, Martin MinerAbstract:AbstractBackground: Although hypogonadism is common in men with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), Testosterone levels after Testosterone replacement therapy (TRT) in this population have not been reported. Methods: The Testim Registry in the United States (TRiUS) was the first prospective, observational registry of men with hypogonadism who were prescribed TRT. The TRiUS cohorts with (n = 82) and without (n = 767) HTV/AIDS were followed during 12 months of treatment with Testim® (1% Testosterone gel; Auxilium Pharmaceuticals, Inc.). Total Testosterone (TT) and free Testosterone levels, symptoms of depression, sexual function, body composition profiles, and prostate-specific antigen levels were evaluated. Results: The HIV/AIDS and non-HIV/AIDS cohorts differed at baseline in age (48.3 vs 52.5 years), TT level (13.0 vs 9.6 nmol/L), duration of hypogonadism (27.1 vs 14.6 months), prior TRT (36.6% vs 22.6%), body mass index (26.5 vs 32.0 kg/m2), and antidepressant (...
-
12-month observation of Testosterone replacement effectiveness in a general population of men.
Postgraduate medicine, 2013Co-Authors: Martin Miner, Rajib K. Bhattacharya, Gary Blick, Harvey Kushner, Mohit KheraAbstract:AbstractBackground: Testosterone decline becomes more prevalent as men age and symptomatic Testosterone deficiency is associated with potentially serious comorbidities. Despite limitations, registries can provide an opportunity to accumulate data regarding disease management in a typical patient population, including diagnosis, treatment, and outcomes. Materials and Methods: The Testim Registry in the United States (TRiUS) was a prospective, 12-month, observational cohort registry of men prescribed Testim® (1% Testosterone gel; Auxilium Pharmaceuticals, Inc.) for the first time; patients previously on other forms of Testosterone replacement therapy (TRT) were eligible to participate in the study as well. The registry recorded total Testosterone (TT) and free Testosterone (FT) levels, prostate-specific antigen (PSA), sexual function, mood/depression, and cardiometabolic and anthropometric criteria before and after TRT. Changes over time were analyzed by analysis of variance, and linear regression and Pears...
-
changes in prostate specific antigen in hypogonadal men after 12 months of Testosterone replacement therapy support for the prostate saturation theory
The Journal of Urology, 2011Co-Authors: Mohit Khera, Rajib K. Bhattacharya, Gary Blick, Harvey Kushner, Dat Nguyen, Martin MinerAbstract:Purpose: We measured prostate specific antigen after 12 months of Testosterone replacement therapy in hypogonadal men.Materials and Methods: Data were collected from the TRiUS (Testim® Registry in the United States), an observational registry of hypogonadal men on Testosterone replacement therapy (849). Participants were Testim naive, had no prostate cancer and received 5 to 10 gm Testim 1% (Testosterone gel) daily.Results: A total of 451 patients with prostate specific antigen and total Testosterone values were divided into group A (197 with total Testosterone less than 250 ng/dl) and group B (254 with total Testosterone 250 ng/dl or greater). The groups differed significantly in free Testosterone and sex hormone-binding globulin, but not in age or prostate specific antigen. In group A but not group B prostate specific antigen correlated significantly with total Testosterone (r = 0.20, p = 0.005), free Testosterone (r = 0.22, p = 0.03) and sex hormone-binding globulin (r = 0.59, p = 0.002) at baseline. A...
-
Baseline data from the TRiUS registry: symptoms and comorbidities of Testosterone deficiency.
Postgraduate medicine, 2011Co-Authors: Martin Miner, Mohit Khera, Rajib K. Bhattacharya, Gary Blick, Harvey KushnerAbstract:AbstractBackground: Testosterone deficiency (TD) is prevalent among men seeking medical attention and may be associated with other comorbidities. Objective: The Testim® Registry in the United States (TRiUS), a large, multicenter, prospective, 12-month observational cohort registry, was established to quantify symptoms and comorbidities of hypogonadal men in real-world clinical settings and to evaluate the effect of Testosterone replacement therapy (TRT). Methods: Eligible TRiUS participants were hypogonadal men prescribed Testim® (1% Testosterone gel) for the first time. Evaluated baseline parameters included: total Testosterone (TT), free Testosterone (FT), sex hormone-binding globulin (SHBG), prostate-specific antigen (PSA), anthropometrics (height, weight, waist, hip, and body mass index [BMI]), lipids, blood glucose, sexual dysfunction, mood/depression, and cardiovascular and metabolic risk factors. Parameters were correlated to TT and age using bivariate correlation and to the combination of TT and a...
Harvey Kushner - One of the best experts on this subject based on the ideXlab platform.
-
Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
Postgraduate medicine, 2013Co-Authors: Gary Blick, Rajib K. Bhattacharya, Mohit Khera, Harvey Kushner, Martin MinerAbstract:AbstractBackground: Although hypogonadism is common in men with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), Testosterone levels after Testosterone replacement therapy (TRT) in this population have not been reported. Methods: The Testim Registry in the United States (TRiUS) was the first prospective, observational registry of men with hypogonadism who were prescribed TRT. The TRiUS cohorts with (n = 82) and without (n = 767) HTV/AIDS were followed during 12 months of treatment with Testim® (1% Testosterone gel; Auxilium Pharmaceuticals, Inc.). Total Testosterone (TT) and free Testosterone levels, symptoms of depression, sexual function, body composition profiles, and prostate-specific antigen levels were evaluated. Results: The HIV/AIDS and non-HIV/AIDS cohorts differed at baseline in age (48.3 vs 52.5 years), TT level (13.0 vs 9.6 nmol/L), duration of hypogonadism (27.1 vs 14.6 months), prior TRT (36.6% vs 22.6%), body mass index (26.5 vs 32.0 kg/m2), and antidepressant (...
-
12-month observation of Testosterone replacement effectiveness in a general population of men.
Postgraduate medicine, 2013Co-Authors: Martin Miner, Rajib K. Bhattacharya, Gary Blick, Harvey Kushner, Mohit KheraAbstract:AbstractBackground: Testosterone decline becomes more prevalent as men age and symptomatic Testosterone deficiency is associated with potentially serious comorbidities. Despite limitations, registries can provide an opportunity to accumulate data regarding disease management in a typical patient population, including diagnosis, treatment, and outcomes. Materials and Methods: The Testim Registry in the United States (TRiUS) was a prospective, 12-month, observational cohort registry of men prescribed Testim® (1% Testosterone gel; Auxilium Pharmaceuticals, Inc.) for the first time; patients previously on other forms of Testosterone replacement therapy (TRT) were eligible to participate in the study as well. The registry recorded total Testosterone (TT) and free Testosterone (FT) levels, prostate-specific antigen (PSA), sexual function, mood/depression, and cardiometabolic and anthropometric criteria before and after TRT. Changes over time were analyzed by analysis of variance, and linear regression and Pears...
-
changes in prostate specific antigen in hypogonadal men after 12 months of Testosterone replacement therapy support for the prostate saturation theory
The Journal of Urology, 2011Co-Authors: Mohit Khera, Rajib K. Bhattacharya, Gary Blick, Harvey Kushner, Dat Nguyen, Martin MinerAbstract:Purpose: We measured prostate specific antigen after 12 months of Testosterone replacement therapy in hypogonadal men.Materials and Methods: Data were collected from the TRiUS (Testim® Registry in the United States), an observational registry of hypogonadal men on Testosterone replacement therapy (849). Participants were Testim naive, had no prostate cancer and received 5 to 10 gm Testim 1% (Testosterone gel) daily.Results: A total of 451 patients with prostate specific antigen and total Testosterone values were divided into group A (197 with total Testosterone less than 250 ng/dl) and group B (254 with total Testosterone 250 ng/dl or greater). The groups differed significantly in free Testosterone and sex hormone-binding globulin, but not in age or prostate specific antigen. In group A but not group B prostate specific antigen correlated significantly with total Testosterone (r = 0.20, p = 0.005), free Testosterone (r = 0.22, p = 0.03) and sex hormone-binding globulin (r = 0.59, p = 0.002) at baseline. A...
-
Baseline data from the TRiUS registry: symptoms and comorbidities of Testosterone deficiency.
Postgraduate medicine, 2011Co-Authors: Martin Miner, Mohit Khera, Rajib K. Bhattacharya, Gary Blick, Harvey KushnerAbstract:AbstractBackground: Testosterone deficiency (TD) is prevalent among men seeking medical attention and may be associated with other comorbidities. Objective: The Testim® Registry in the United States (TRiUS), a large, multicenter, prospective, 12-month observational cohort registry, was established to quantify symptoms and comorbidities of hypogonadal men in real-world clinical settings and to evaluate the effect of Testosterone replacement therapy (TRT). Methods: Eligible TRiUS participants were hypogonadal men prescribed Testim® (1% Testosterone gel) for the first time. Evaluated baseline parameters included: total Testosterone (TT), free Testosterone (FT), sex hormone-binding globulin (SHBG), prostate-specific antigen (PSA), anthropometrics (height, weight, waist, hip, and body mass index [BMI]), lipids, blood glucose, sexual dysfunction, mood/depression, and cardiovascular and metabolic risk factors. Parameters were correlated to TT and age using bivariate correlation and to the combination of TT and a...
Katarzyna Tyszczuk - One of the best experts on this subject based on the ideXlab platform.
-
Application of an in situ plated lead film electrode to the analysis of Testosterone by adsorptive stripping voltammetry
Analytical and bioanalytical chemistry, 2008Co-Authors: Katarzyna TyszczukAbstract:Adsorptive stripping voltammetry is a very sensitive and selective method for determination of drugs and organic substances in biological fluids. We have shown that determination of Testosterone by adsorptive stripping voltammetry is possible using a lead film electrode. The lead film plating process and accumulation of Testosterone were performed simultaneously from an acetate buffer solution of pH = 5.2 at a potential of −1.1 V. The measurements were carried out in undeaerated solutions. The detection limit was 9 × 10−9 mol L−1 for an accumulation time of 120 s; the relative standard deviation for 1 × 10−7 mol L−1 Testosterone was 3.8%. The proposed voltammetric procedure for determination of Testosterone could be applied to its determination in a pharmaceutical preparation and human urine samples directly without any separation steps.
